PDSB · Pds Biotechnology Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.46M | - | $4.58M | $4.21M | $5.83M | - | $6.80M | $4.53M | $6.70M | - |
| SG&A | $3.06M | - | $3.56M | $3.41M | $3.27M | - | $3.37M | $4.16M | $3.39M | - |
| Total Operating Expenses | $6.52M | - | $8.14M | $7.62M | $9.11M | - | $10.18M | $8.68M | $10.10M | - |
| D&A | $5.5K | - | - | - | $5.5K | - | - | - | $4.7K | - |
| Operating Income | ($6.52M) | - | ($8.14M) | ($7.62M) | ($9.11M) | - | ($10.18M) | ($8.68M) | ($10.10M) | - |
| Interest Expense | $1.01M | - | $1.15M | $2.14M | $1.17M | - | $1.21M | $1.18M | $1.17M | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | ($869.2K) | - | - |
| Net Income | ($7.35M) | - | ($9.01M) | ($9.43M) | ($8.49M) | - | ($10.73M) | ($8.33M) | ($10.60M) | - |
| EPS - Basic | ($0.13) | - | ($0.19) | ($0.21) | ($0.21) | - | ($0.29) | ($0.23) | ($0.30) | - |
| EPS - Diluted | ($0.13) | - | ($0.19) | ($0.21) | ($0.21) | - | ($0.29) | ($0.23) | ($0.30) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.66M | $26.71M | $26.20M | $31.87M | $39.98M | $41.69M | $49.75M | $57.73M | $66.63M | $56.56M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.65M | $3.57M | $5.18M | $4.50M | $2.86M | $1.68M | $1.30M | $3.25M | $6.00M | $6.98M |
| Current Assets | $22.89M | $28.25M | $27.89M | $33.65M | $42.47M | $45.05M | $52.13M | $60.16M | $68.69M | $59.06M |
| Total Assets | $24.66M | $30.49M | $34.71M | $40.48M | $47.03M | $45.36M | $52.45M | $60.50M | $69.01M | $59.39M |
| Current Liabilities | $10.15M | $9.48M | $13.33M | $11.53M | $18.27M | $17.09M | $18.34M | $15.67M | $15.06M | $13.63M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $20.77M | $21.24M | $25.25M | $24.52M | $24.67M | $26.35M | $30.45M | $29.58M | $31.82M | $33.26M |
| Stockholders' Equity | $3.89M | $9.25M | $9.45M | $15.96M | $22.36M | $19.00M | $22.00M | $30.92M | $37.18M | $26.13M |
| Retained Earnings | ($223.96M) | ($216.61M) | ($209.04M) | ($200.03M) | ($190.60M) | ($182.11M) | ($174.16M) | ($163.43M) | ($155.10M) | ($144.50M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.37M) | - | - | - | ($9.03M) | - | - | - | ($9.94M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | ($679.8K) | - | - | - | $7.32M | - | - | - | $20.01M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -29.8% | - | -26.0% | -23.3% | -18.1% | - | -20.5% | -13.8% | -15.4% | - |
| Return on equity | -188.8% | - | -95.3% | -59.1% | -38.0% | - | -48.8% | -26.9% | -28.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.26 | 2.98 | 2.09 | 2.92 | 2.33 | 2.64 | 2.84 | 3.84 | 4.56 | 4.33 |
| Quick ratio | 2.26 | 2.98 | 2.09 | 2.92 | 2.33 | 2.64 | 2.84 | 3.84 | 4.56 | 4.33 |
| Cash ratio | 2.13 | 2.82 | 1.97 | 2.76 | 2.19 | 2.44 | 2.71 | 3.68 | 4.42 | 4.15 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -6.4x | - | -7.1x | -3.6x | -7.8x | - | -8.4x | -7.3x | -8.6x | - |
| Equity multiplier | 6.34 | 3.30 | 3.67 | 2.54 | 2.10 | 2.39 | 2.38 | 1.96 | 1.86 | 2.27 |
| Liabilities / Assets | 0.84 | 0.70 | 0.73 | 0.61 | 0.52 | 0.58 | 0.58 | 0.49 | 0.46 | 0.56 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 8.6x | - | 5.0x | 3.8x | 2.2x | - | 6.4x | 3.5x | 3.7x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 28.4% | - | 20.0% | 12.2% | 9.8% | - | 3.2% | 31.6% | -7.2% | - |
| Net income growth (YoY) | 13.4% | - | 16.0% | -13.3% | 19.9% | - | 1.1% | 27.8% | -9.8% | - |
| EPS growth (YoY) | 38.1% | - | 34.5% | 8.7% | 30.0% | - | 17.1% | 37.8% | 6.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -82.6% | -51.3% | -57.0% | -48.4% | -39.9% | -27.3% | -10.1% | -4.7% | -9.3% | -40.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PDS Biotechnology Corp against the 5 most active filers in the same SIC group.